Estrella Immunopharma

Estrella Immunopharma is a clinical-stage biotechnology company developing next-generation T-cell immunotherapies for cancer and autoimmune diseases. The company's core technology is its proprietary CD19-Redirected ARTEMIS T Cell platform, designed to mitigate severe side effects like cytokine release syndrome (CRS) while maintaining efficacy. Estrella is applying this platform to both hematologic malignancies and, via a 'mark-and-kill' approach using oncolytic viruses, to solid tumors.